TECH – Prenuvo, a leader in proactive whole-body MRI screening, has announced a significant expansion of its health services following a successful $120 million Series B funding round in 2024. The financing was co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis. This investment aims to enhance Prenuvo’s core MRI screening capabilities by integrating additional health assessments and advanced analyses.
A notable development is Prenuvo’s recent FDA clearance for its AI-powered Body Composition report. This innovative platform provides precise, actionable data on various health metrics, including visceral and subcutaneous fat, liver fat, muscle volumes, and the size of vital abdominal organs. The personalized reports generated enable individuals to make informed lifestyle choices and proactive health decisions. In addition to the Body Composition report, Prenuvo is introducing a comprehensive brain health scan. This service offers insights into brain function, cognitive health, and early indicators of neurodegenerative diseases, aiming to facilitate early detection and intervention.
Complementing these imaging services, Prenuvo is launching a blood biomarker assessment panel. This extensive analysis evaluates metabolic, cardiovascular, hormonal, and immune health, providing a holistic view of an individual’s well-being. The integration of imaging and blood biomarkers is designed to deepen health insights and promote a more comprehensive understanding of one’s health status. To make these services more accessible, Prenuvo is rolling out an “Enhanced Screening” package. Priced at $3,999, this 75-minute bundled service includes the full suite of new offerings. Initially available in Silicon Valley, Los Angeles, and New York City (at $4,499), the company plans to extend this package to other locations in the spring.
Since its inception, Prenuvo has conducted over 100,000 scans, identifying more than 1.4 million personalized health insights for its 110,000 members. This milestone underscores the company’s commitment to proactive healthcare and early disease detection. CEO Andrew Lacy emphasized Prenuvo’s mission, stating, “We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge.” This approach reflects a shift towards preventive healthcare, leveraging cutting-edge technology and comprehensive health assessments to promote longer, healthier lives. With 17 centers across North America and plans to expand to Europe and Australia, Prenuvo is poised to make proactive healthcare more accessible globally. The recent funding and service expansions position the company at the forefront of preventive health innovation.
